HaSNPV几丁质酶重组蛋白的表达、纯化和复性

棉铃虫单核衣壳核型多角体病毒（HaSNPV）是我国第一个商品病毒杀虫剂,具有使用安全、害虫不产生抗药性等优点,是一种很有发展潜力的生物农药。幼虫虫体受病毒感染后,HaSNPV几丁质酶在其液化过程中起了很大的作用,因此可以作为增效剂以显著提高细菌、病毒、真菌等微生物杀虫剂的毒力,并具有更高的安全性。将HaSNPV几丁质酶基因构建到原核表达载体pET28a中,经测序检验后转化至大肠杆菌Rosetta,然后以IPTG作为诱导剂,目标蛋白以包涵体的形式得以成功表达。在变性条件下,包涵体经镍 次氮基三乙酸(Ni-NTA)柱层析纯化,并以两种不同的方法进行复性,均可获得具有活性的HaSNPV几丁质酶。     

Overexpression, refolding, purification of Erbin PDZ domain from Escherichia coli and preparation of its polyclonal antibody

The Erbin was recently identified. The antibody against Erbin has not been commercially available. As a new member of peripheral protein LAP family and novel type of adaptor protein, its functions and binding partners are not completely known. In the present study, cDNA encoding PDZ domain of Erbin was inserted in a prokaryotic expression vector. His-tagged recombinant protein was overproduced in E. coli and purified by Ni-NTA column chromatography. About 14.4 mg of the purified protein was obtained from 500 mL of cell culture. The purity of the recombinant protein was higher than 90%. The polyclonal antibody against this protein was raised. The antibody can recognize both denatured and natural Erbin protein. It will be used to further identify the new binding partners of Erbin and study its unknown functions.     

Purification and characterization of recombinant extracellular domain of human HER2 from Escherichia coli

The human epidermal growth factor receptor 2 (HER2) is a member of the epidermal growth factor receptor (EGFR) family, and it plays an important role in the development of many human adenocarcinomas. The extracellular domain (ECD) of HER2 is an ideal target for therapeutic approaches. In order to obtain large quantities of active HER2 ECD protein for biochemical and structural analysis and for detecting anti-HER2 ECD antibodies in serum, a systematic assessment of optimal parameters for the refolding of the glutathione S-transferase (GST) fusion protein was carried out. After the GST-HER2 ECD inclusion bodies were solubilized with denaturation buffer containing 8M urea, an approach was then used to optimize refolding parameters. This approach utilized dilution of denatured and reduced GST-HER2 ECD into different refolding buffers using orthogonal design method. Optimal refolding was obtained in an alkaline buffer containing reduced and oxidized glutathione, and subsequent incubation at 4 degrees C for 24h. After purification with glutathione Sepharose 4B and PreScission protease cleavage of the fusion protein, 8.9mg of recombinant HER2 ECD was obtained from 1L of Escherichia coli. Rabbit polyclonal antibodies against HER2 ECD were obtained. The purified protein was found to be immunogenic and useful for immunodiagnostic studies of serum HER2 ECD and its antibodies by using enzyme-linked immunosorbent assay (ELISA).     

Purification and refolding of human alpha5-subunit (PSMA5) of the 20S proteasome, expressed as inclusion bodies in Escherichia coli

The 20S proteasome is the central enzyme of nonlysosomal protein degradation in both the cytosol and nucleus. It is composed of 28 protein subunits which are arranged into four staggered heptameric rings. The outer rings consist of alpha-subunits which are responsible for binding of proteasome activators, inhibitors, and regulators. To better characterize human alpha5-subunit (PSMA5) of the 20S proteasome, we have established a high-efficiency Escherichia coli expression system. The DNA-coding sequence for the human PSMA5, which was subcloned into the vector pET-22b (+), has been expressed as inclusion bodies in E. coli BL21 (DE3). To produce the native PSMA5, straightforward protocols have been developed for refolding the human PSMA5 in the presence of surfactants using dilution refolding and size-exclusion chromatography matrix refolding methods. After refolding, recovery yields of about 20% were obtained, respectively, with purity above 95%. The human PSMA5 was detected by dynamic light scattering in refolding process, and the molecular weight of the final refolded product was measured using gel filtration chromatography, which indicates that the human PSMA5 exists mainly as tetramer.     

伴侣分子（GroE）纯化及其催化的重组蛋白质折叠反应

我们自Ｅ．ｃｏｌｉ细胞中纯化出ＧｒｏＥＬ和ＧｒｏＥＳ,对其有活性的分子状态和反应条件进行了探索,结果表明,只有在等摩尔的ＧｒｏＥＬ和ＧｒｏＥＳ以及１ｍｍｏｌ／ＬＡＴＰ和适当浓度的Ｋ＋存在时;才会有较高的催化折叠效率,它可使ｌｍｇ／ｍｌ的ＩＬ－２的正确折叠率由３０％提高到５８％,使ＩＬ－２和ＧＭ－ＣＳＦ的比活性提高１倍以上。它提高重组蛋白质正确拆叠率的关键是可以降低折叠过程中形成聚合体。     

大连蛇岛蝮蛇类凝血酶在大肠杆菌中的表达与纯化

将编码大连蛇岛蝮蛇类凝血酶 (Gloshedobin)的基因克隆于表达载体pET-32a( + )中 ,以融合蛋白形式在大肠杆菌中获得表达。在 2 5℃下经 1mmol/LIPTG诱导 6h ,SDS-PAGE和蛋白质印迹分析表明 ,部分融合蛋白以可溶形式存在于大肠杆菌的细胞质中。针对金属螯合亲和层析分离某些含His-标签重组蛋白质时专一性不高 ,并且存在配基泄漏的缺陷 ,设计合成了以抗重组类凝血酶的鸡卵黄免疫球蛋白为配基的免疫亲和层析柱。通过疏水色谱OctylSepharoseFF ,IgY免疫亲和层析以及强阴离子交换色谱SourceQ等三步柱色谱分离纯化获得比活力为 454.7U/mg的重组蛇毒类凝血酶 ,活力回收率为 34.8%。蛋白质印迹分析和纤维蛋白原凝结活性分析表明 ,该表达产物具有相应的免疫活性和酶活性     

肠三叶因子在大肠杆菌中的表达、纯化及其抗体制备

目的:获得肠三叶因子(ITF)的原核表达产物及抗rITF抗体,为深入研究ITF的作用机制及其受体研究奠定基础。方法:常规提取人小肠组织总RNA,用RT-PCR获得ITF编码基因片段,克隆至质粒pET32a获得原核表达栽体,双酶切和测序后转化至Origami B(DE3)用IPTG诱导表达,优化条件获得最大表达产量;用SDS-PAGE、Western blot鉴定表达产物,亲和层析纯化获得的重组蛋白rITF皮下多点注射家兔,制备多克隆抗体,并用此抗体进行大鼠肠组织免疫组化研究。结果:测序证实PCR扩增获得ITF全长基因序列与基因文库中的完全一致,将该基因片段正确插入表达载体pET32a中、优化表达条件后,重组蛋白的表达量达到50mg/L;Western blot证明重组蛋白具有良好的抗原性和特异性;通过Ni-NTA亲和层析、超滤离心后,得到90%纯度的蛋白;收集兔血清,纯化后获得特异性良好的ITF抗体,免疫组化染色肠组织显示ITF表达的部位定位于杯状细胞。结论:成功构建了表达载体pET32a-ITF,在大肠杆菌中表达并纯化获得纯度较高的rITF,并获得了生物活性较高的ITF抗体,ITF主要在肠道杯状细胞分泌表达。     

沙门菌毒力基因spvB的原核表达及其多克隆抗体的制备

目的:构建沙门菌毒力基因spvB的原核表达载体,诱导表达纯化SpvB蛋白并以其为抗原免疫小鼠,制备多克隆抗体。方法:利用生物信息学软件对SpvB进行分析,选取抗原性较高、易表达的氨基酸序列作为克隆序列,以携带spvB基因的鼠伤寒沙门菌为模板,PCR扩增目的片段后与原核表达载体pET28a(+)连接;将质粒pET28a-SpvB转化大肠埃希菌BL21(DE3)后诱导表达并纯化。目的蛋白免疫小鼠,制备抗SpvB多克隆抗体,Western blot检测抗体特异性。结果:成功构建spvB原核表达载体,经IPTG诱导结果显示,重组蛋白表达且主要存在于包涵体中,将纯化后的蛋白免疫小鼠Western blot检测血清中抗体与SpvB特异性结合。结论:获得具有免疫原性的SpvB蛋白及其多克隆抗体,为进一步研究该基因的功能奠定基础。     

人类免疫缺陷病毒Ⅰ型核心蛋白(p24)在大肠杆菌中的表达、纯化及鉴定

在大肠杆菌中,利用新构建的含T7g-10L RBS以及λ-PR启动子的新型原核表达载体,通过表达gag-pol基因片段,获得了具有天然序列的人类免疫缺陷病毒1型(HIV-1)核心蛋白p24的高效表达。克隆的gag-pol基因片段在其阅读框架移位区域插入了4bp碱基,其表达的病毒蛋白酶在阅读框架上与gag一致,从而实现了对gag-pol融合蛋白的有效加工,产生成熟的核心蛋白p24及其它产物。重组p24以可溶形式存在,可以被抗p24的单克隆抗体特异识别。测定的N端8个氨基酸序列与从病毒纯化的p24完全一致。在使用硫酸铵沉淀后,采用两步离子柱层析,可将重组蛋白纯化到95％以上的纯度。结果表明,纯化的p24可以作为特异性很强的试剂而用于HIV感染的诊断及病情的预后,并可用于p24的生化及结构分析。     

gcm蛋白的表达、纯化及多克隆抗体的制备

gcm(glial cells missing)是调控神经元细胞和神经胶质细胞相互转化的一个基因开关.在gcm功能缺损的突变体中,预期的神经胶质细胞发育成神经元细胞;而在gcm过表达的突变体中,预期的神经元细胞转化为神经胶质细胞.此外,gcm还调控血浆细胞发育.为了进一步研究gcm在发育中的功能,需要获得gcm蛋白并制备其抗体.根据已报道的gcm基因序列,以果蝇cDNA文库为模板进行PCR扩增得到gcm部分编码区序列,然后将其连接到pET-28a载体以获得原核表达载体.重组载体经酶切测序鉴定确认后,转化大肠杆菌(E.coli)BL21,并用IPTG诱导融合蛋白表达.采用Ni-IDA凝胶柱亲和纯化蛋白,将纯化的His-gcm融合蛋白免疫新西兰大白兔制备多克隆抗体,并用Western Blot检测抗体效价.获得的gcm原核表达重组融合蛋白及高效价的特异性兔抗gcm多克隆抗体,为gcm功能的进一步研究奠定了基础.     

Cloning, Overexpression and Purification of Bacillus subtilis Elongation Factor Tu in Escherichia coli

To establish the overexpression and one-step purification system of Bacillus subtilis elongation factor-Tu (EF-Tu), the EF-Tu gene was amplified with or without own ribosome binding site (rbs) by PCR and the only PCR product without rbs was subcloned successfully. For the expression of the EF-Tu gene cloned after PCR amplification, a constitutive expression system and inducible expression system with His₆ tag at N-terminus or C-terminus, or glutathione-S-transferase (GST) fusion system were examined in E. coli and B. subtilis. Except GST fusion system in E. coli, however, all other trials were unsuccessful at the step of plasmid construction for the EF-Tu expression. The GST/EF-Tu fusion proteins were highly expressed by IPTG induction and obtained as both soluble and insoluble form. From the soluble GST/EF-Tu fusion protein, EF-Tu was obtained to near homogeneity by one-step purification with glutathione-sepharose affinity column chromatography followed by factor Xa treatment. The purified EF-Tu showed high GDP binding activity. These results indicate that the GST/EF-Tu fusion system is favorable to overexpression and purification of B. subtilis EF-Tu.     

人前列腺特异膜抗原膜外区基因的克隆表达及抗体的制备

利用RT PCR技术 ,从前列腺癌组织总RNA中扩增人前列腺特异膜抗原 (PSMA)基因编码区序列 ,克隆至pcDNA3.1载体 ,以此为模板再次PCR扩增出PSMA膜外区cDNA(edPSMA) ,序列测定表明克隆获得的PSMA及edPSMA与基因库所登录的序列相一致。构建原核表达质粒pMAL c2x edPSMA ,经IPTG诱导表达的MBP edPSMA融合蛋白分子量约 12 0kD ,Westernblot证实表达产物可特异地与PSMA单克隆抗体 4G5结合。用直链淀粉琼脂糖凝胶 (Amyloseresin)亲和层析纯化蛋白质可得到电泳均一的融合蛋白 ,免疫BALB C小鼠制备多抗 ,获得效价为 1∶12 80 0的多克隆抗体 ,该抗体可用于前列腺癌组织标本PSMA表达的检测     

Codon optimization of MTS1 and its expression in Escherichia coli

MTS1, which encodes a protein named p16, is an important gene involved in tumorigenesis. To increase the expression of p16 in Escherichia coli, MTS1 was synthesized de novo by recursive PCR, with codons optimized towards E. coli. Studies indicate that N-terminal amino acids of p16 had negative impact on its expression in E. coli. The function of p16DeltaN8 is not affected by the absence of N-terminal eight amino acids, compared with p16. p16DeltaN8 was expressed in E. coli, which reached 22% of total cell proteins. Purified p16DeltaN8 (purity was 98%) was delivered into A875 (melanoma), MCF7 (breast cancer), and HeLa (cervical cancer) cells by lipofectin. Results show purified p16DeltaN8 remarkably inhibited the growth of A875 and MCF7 cells, whereas it had little effect on HeLa cells.     

人热休克蛋白gp96基因的克隆及其在大肠杆菌中的表达与纯化

热休克蛋白gp96是热休克蛋白90家族成员,能够引起非特异性和特异性免疫反应。得到大量高纯度的蛋白质是研究开发gp96的关键。然而重组的gp96容易在E．coli中降解,并在一定条件下形成多聚体。实验先将人gp96基因克隆到pET-30a载体上并在E．coli Blstar中表达,再经过亲和层析、阴离子交换、分子筛分别纯化gp96。最终去掉了大部分的降解片段和多聚体,得到一定量的可溶性gp96,为进一步研究其结构和功能打下一定的基础。     

大鼠丝氨酸或半胱氨酸蛋白酶抑制剂B2的表达、纯化及抗体制备

目的:原核表达、纯化大鼠丝氨酸或半胱氨酸蛋白酶抑制剂B2(SERPINB2),并制备其多克隆抗体.方法:设计扩增大鼠Serpinb2全长基因的特异引物,通过PCR扩增出该基因片段,测序正确后插入含GST基因的原核表达载体pGEX-KG中,以IPTG诱导表达,并经谷胱甘肽琼脂糖珠纯化融合蛋白;用纯化的蛋白免疫小鼠制备多克...     

树鼩IgG纯化鉴定及其多克隆抗体制备和检测

目的:比较两种抗体纯化方法在分离纯化树鼩IgG抗体的应用,制备抗IgG的多克隆抗体及检测。方法:采用两种商品化IgG抗体纯化试剂盒分离树鼩血清IgG抗体,采用SDS-PAGE和蛋白定量测定提纯IgG。以树鼩IgG作为抗原,与等量弗氏完全佐剂(第一次)、弗氏不完全佐剂(第二次)混合皮下注射免疫兔,对分离血清进行多克隆抗体纯化及Western Blot检测及定量分析。结果:两种方法均能有效分离纯化树鼩IgG,在经过Montage PROSEP-A试剂纯化后的IgG在纯度和含量方面均优于Protein A/G Matrix试剂。通过纯化后的树鼩IgG免疫兔制备的抗IgG抗体能有效识别树鼩IgG。结论:纯化的树鼩IgG具有良好免疫原性,由此制备的抗体具有高度特异性。研究结果为利用树鼩作为实验动物提供了必要的实验基础。     

重组酶Exo的纯化及多克隆抗体制备

目的:纯化Exo重组酶融合蛋白并制备相应抗体。方法:用阴离子交换柱对蛋白进行初步纯化,然后用Ni-NTA介质填充的层析柱分离纯化含His标签的融合蛋白,用谷胱甘肽琼脂糖4B介质填充的层析柱分离纯化GST融合蛋白;二次纯化的蛋白利用硝酸纤维素膜结合法制备抗原蛋白并免疫实验动物。结果:ELISA结果显示血清抗体效价可达到1∶12 800,说明通过Western免疫印迹自制的多克隆抗体能特异地与Exo重组蛋白相互作用。结论:该蛋白纯化方法操作简单,制备的抗原纯度高,多克隆抗体特异性好。     

Purification and on-column refolding of EGFP overexpressed as inclusion bodies in Escherichia coli with expanded bed anion exchange chromatography

The enhanced green fluorescent protein (EGFP) was over-expressed in Escherichia coli as inclusion bodies to increase its quantity and to facilitate its purification. Insoluble EGFP has been purified on Q Hyper Z matrix by expanded bed adsorption after solubilization in 8 M urea. The adsorption was made in expanded bed mode to avoid centrifugation. EBA-column refolding was done by elimination of urea and elution with NaCl. The EGFP was obtained as a highly purified soluble form with similar behavior in fluorescence and electrophoresis as native EGFP.     

抑癌蛋白PTEN的原核表达、抑癌活性研究和抗体制备

PTEN是具有蛋白质和酯类双重特异性磷酸酶活性的抑癌蛋白,在肿瘤治疗中具有广阔的应用前景。鉴于原核表达PTEN蛋白并用于抑癌实验的研究尚未见报道,因此尝试利用大肠杆菌表达有活性的PTEN蛋白,检测其抑癌效果。利用本室克隆的PTEN基因cDNA和原核表达载体pET44a( )分别构建带6×His和Nus标签的两种诱导型原核融合表达载体pETPTEN和pETNusPTEN,在不同的大肠杆菌表达宿主BL21(DE3)(简写为BL)和Rosettagami(DE3)pLysS(简写为RG)中诱导表达。SDSPAGE和Westernblot检测表明:在可溶性组分和包涵体中均含有目的蛋白,在BL中目的蛋白的表达量较高(18.7%)而在RG中可溶性蛋白的比例较高(6.6%)。经纯化和包涵体蛋白复性处理后,重组融合蛋白经Chariot转运入小鼠实体瘤及人前列腺癌DU145细胞。抑癌实验表明:与对照组相比,重组PTEN蛋白对小鼠实体瘤的生长抑制率为58.76%;对癌细胞DU145的生长抑制率可达46.16%;并可导致明显的G0G1期阻滞,其中在宿主RG中表达的重组蛋白抑癌效果明显高于BL宿主中表达的目的蛋白。证实在原核系统中表达的重组PTEN蛋白具有抑癌活性,同时制备了PTEN的高效价腹水多抗,为深入研究PTEN蛋白在癌症治疗中的应用打下了良好的基础。